The emerging, expected evidence that #vaccines reduce transmission is a game-changer, but the focus on herd immunity can give the impression that we won’t see a benefit until most are vaccinated. Not true. 1/ @apoorva_nyc
The value of transmission-reducing vaccines begins well before two people make contact. By reducing infections in a community, vaccines make it less likely for either of those persons to be carrying the virus, reducing risk substantially. 3/ @erinbanco politico.com/news/2021/03/0…
If a vaccinated person IS exposed, they’re less likely to pass virus to others because:
🔹The vaccine prevents them from being infected; OR
🔹If infected, they're less infectious because symptoms are reduced and/or they shed less virus. 4/
Instead of being a link in a chain of transmission, a vaccinated person can be the end of that chain.
The more people vaccinated, the more chains terminated, and the fewer branches on the chains that continue. 5/
And any vaccinated person who is infected is almost certainly protected from severe disease and death.
We don’t need herd immunity or 100% reduction of transmission to see these benefits. 6/
Every time a person is vaccinated, it gets a little harder for the virus to be transmitted through a community, and that reduces the risk of *any* interaction in a community by a small degree.
So every person who is vaccinated is helping to protect the *entire* community. 7/
And just as virus transmission is exponential, so is the impact of a transmission-reducing vaccine on cases in a community. 8/
If this sounds like the argument for wearing masks, it should. Vaccination can protect both the person vaccinated as well as the people around them. But unlike masks, vaccine protection works 24/7 without a person even thinking about it. 9/
Because vaccines are unlikely to be 100% effective at stopping transmission, vaccinated people should wear masks around unvaccinated people as long as (a) a lot of virus is circulating; and (b) many people remain unvaccinated. But this will be relaxed & removed over time. 10/
We need to learn more about the impact of vaccination and individual vaccines on transmission, but any effect will be helpful, and the early evidence and prior experience is very promising. 11/
If we can achieve global equitable access to any of the vaccines that have been shown to be safe & effective, which is our moral obligation, they’ll help us to bring an end to the worst human, economic and societal impact of this pandemic. Everyone has a role to play. 12/end
For those who haven't seen the full thread, these statements only apply to vaccines that reduce transmission.
My goal was to illustrate that these vaccines can have a meaningful impact in the absence of herd immunity or 100% prevention of transmission.
More about the complexity of "traditional" vaccine approaches below.
These timelines assume the process has been "scaled up" and everything is in place & ready to go: facility, equipment, raw materials, etc. Unexpected issues can add weeks or months. 2/
As variants spread and #vaccines are deployed, we’re not sequencing enough to keep up w/the virus.
As a stopgap, we should sequence viruses from every vaccinated person who develops #COVID to identify vaccine escape mutations. 1/ washingtonpost.com/health/2021/01…
We call these “vaccine breakthroughs,” and we’ll see more of them as the B.1.351 and P.1 variants spread. Sequencing all breakthrough viruses will help us to track those variants and identify new mutations that might contribute to vaccine escape. 2/
Back in October, I said the Warp Speed timelines were extraordinarily optimistic given the inherent risks of vaccine development, manufacturing and distribution. All of those risks and others have materialized. 1/
Much of the risk is in "scaling up" production to produce large volumes of vaccine in a facility, and “scaling out” to manufacturing partners to expand capacity. This thread is about vaccine manufacturing and the challenges we’ll continue to face. 2/
The good news is we're likely to see higher levels of vaccine efficacy against variant-associated severe disease and death. J&J has provided the first evidence of this in their press release (insufficient severe dz in the Novavax interim analysis). 3/
@BhadeliaMD@kavitapmd@ashishkjha@ASlavitt@RanuDhillon@RebeccaKatz5 Manufacturing partnerships are necessary for any company to ramp up manufacturing of #COVID vaccines, since no company has enough capacity to meet the world’s needs. Nearly all vaccines in late-stage trials have partnerships in place for this purpose. 1/ 🧵
TIMELINES: Depending on maturity and complexity of the process and partner capabilities, it takes a *minimum* of several months to transfer manufacturing to a new partner & facility. 3/
This table and thread focuses on the AZ vaccine, where more data on a delayed second dose is available than with the Pfizer vaccine. It is not intended to address questions about single-dose regimens or mix & match approaches. 3/